Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
MK-4830 Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562631
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG4, lambda
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
靶标信息
MK-4830 is a humanized IgG4 monoclonal antibody that targets the inhibitory receptor ILT4 (Immunoglobulin-like transcript 4) known for its role in suppressing immune responses by interacting with HLA-G and other MHC class I molecules. Developed by Merck MK-4830 is designed to block ILT4 signaling in myeloid cells enhancing anti-tumor immunity. In tumor environments ILT4's immunosuppressive effects can aid cancer cell evasion from immune surveillance making MK-4830 a strategic agent for immunotherapy particularly in combination with checkpoint inhibitors like pembrolizumab. Clinical trials are underway to assess MK-4830's safety pharmacokinetics and efficacy as a monotherapy and in combination regimens in patients with advanced solid tumors. Studies are focused on optimizing dosage and understanding its mechanism in potentiating immune cell activation to combat cancer highlighting MK-4830's potential in enhancing immune checkpoint blockade strategies.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
